- Home
- SNAL vs CALC Comparison
SNAL vs CALC Comparison
Compare SNAL & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNAL
- CALC
- Stock Information
- Founded
- SNAL 2000
- CALC 2011
- Country
- SNAL United States
- CALC United States
- Employees
- SNAL N/A
- CALC N/A
- Industry
- SNAL Computer Software: Prepackaged Software
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- SNAL Technology
- CALC Health Care
- Exchange
- SNAL Nasdaq
- CALC Nasdaq
- Market Cap
- SNAL 45.1M
- CALC 45.4M
- IPO Year
- SNAL 2022
- CALC N/A
- Fundamental
- Price
- SNAL $0.91
- CALC $3.18
- Analyst Decision
- SNAL
- CALC Strong Buy
- Analyst Count
- SNAL 0
- CALC 2
- Target Price
- SNAL N/A
- CALC $14.50
- AVG Volume (30 Days)
- SNAL 48.5K
- CALC 24.6K
- Earning Date
- SNAL 11-12-2025
- CALC 11-12-2025
- Dividend Yield
- SNAL N/A
- CALC N/A
- EPS Growth
- SNAL N/A
- CALC N/A
- EPS
- SNAL N/A
- CALC N/A
- Revenue
- SNAL $82,330,445.00
- CALC N/A
- Revenue This Year
- SNAL $13.87
- CALC N/A
- Revenue Next Year
- SNAL $26.20
- CALC N/A
- P/E Ratio
- SNAL N/A
- CALC N/A
- Revenue Growth
- SNAL N/A
- CALC N/A
- 52 Week Low
- SNAL $0.64
- CALC $1.42
- 52 Week High
- SNAL $3.42
- CALC $4.26
- Technical
- Relative Strength Index (RSI)
- SNAL 42.53
- CALC 52.92
- Support Level
- SNAL $0.88
- CALC $3.00
- Resistance Level
- SNAL $0.93
- CALC $3.35
- Average True Range (ATR)
- SNAL 0.05
- CALC 0.19
- MACD
- SNAL -0.01
- CALC 0.01
- Stochastic Oscillator
- SNAL 22.33
- CALC 52.27
About SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.